This site is intended for health professionals only!

Published on 17 September 2009

Share this story:
Twitter
LinkedIn

Rituxan passes test for lymphoma

teaser

Roche and Biogen Idec’s cancer drug Rituxan has been found to extend the lives of follicular lymphoma patients, according to a late-stage study.

The disease is a common, incurable but slow-developing form of non-Hodgkin’s lymphoma (NHL) and accounts for about one in four of all cases.

The study was stopped early after Rituxan, known as MabThera outside the US, met its target of extending the time patients live with their disease under control during a pre-planned interim analysis. Rituxan is co-marketed by Genentech.

Copyright Press Association 2009

Roche



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn